University of Cincinnati Cancer Center Identifies Overlooked Genetic Mutations and Fat Tissue Biomarkers to Refine Precision Oncology

UC researchers reveal how "silent" KRAS mutations and fat tissue influence cancer treatment resistance. Discover the latest oncology breakthroughs from AACR 2026.

By: AXL Media

Published: Apr 18, 2026, 10:44 AM EDT

Source: Information for this report was sourced from EurekAlert!

Challenging the Definition of Silent Genetic Mutations

The long-held scientific assumption that "silent" or synonymous mutations have no biological impact is being directly challenged by new research into the KRAS oncogene. While these genetic variants do not alter a gene's amino acid sequence, a team led by Dr. Megan Satyadi has discovered that they can significantly influence tumor behavior. In pancreatic cancer, where KRAS mutations are present in over 90% of cases, these previously ignored variants appear to increase gene expression and help cancer cells develop resistance to targeted inhibitors. This discovery suggests that patients currently classified as having "wild-type" or non-mutated tumors may actually possess oncogenic activity that requires clinical attention.

Fat Tissue as a Noninvasive Predictor for Immunotherapy

In the field of head and neck cancer, researchers have identified a potential noninvasive biomarker located in the fat tissue directly surrounding a tumor. Kyle Harris and his team conducted a retrospective analysis of patients treated with the immunotherapy drug pembrolizumab, finding that a higher volume of peritumoral adipose tissue on CT scans correlated with better survival and pathologic responses. Unlike current FDA-approved biomarkers that require invasive tissue sampling, this imaging-based approach could allow clinicians to predict treatment success using routine scans. Molecular analysis further revealed specific RNA pathways that explain why this localized fat tissue supports a more robust immune response against squamous cell carcinoma.

Disrupting the Support Systems of Melanoma Cells

Research into the tumor microenvironment has uncovered how non-cancerous cells, known as cancer-associated fibroblasts or CAFs, actively shield melanoma from treatment. Graduate assistant Jie Wang identified a specific signaling pathway, the β-catenin–TCF–POSTN axis, which CAFs use to remodel the extracellular matrix and sustain tumor survival during BRAF inhibitor therapy. By targeting this interaction, medical professionals may be able to break down the protective "stroma" around a tumor. The study supports a dual-action treatment strategy that combines standard BRAF inhibitors with drugs designed to disrupt these fibroblast-driven resistance mechanisms.